Profiel
Paul van Slyke formerly worked at Vasomune Therapeutics, Inc., as Chief Scientific Officer, Sairiyo Therapeutics, Inc., as Chief Scientific Officer, and Pharmadrug, Inc., as Chief Scientific Officer from 2021 to 2023.
Dr. van Slyke received his doctorate degree from the University of Toronto.
Eerdere bekende functies van Paul van Slyke
| Bedrijven | Functie | Einde |
|---|---|---|
| PHARMADRUG INC. | Hoofd Techniek/Wetenschap/O&O | 01-05-2023 |
Sairiyo Therapeutics, Inc.
Sairiyo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures psychedelics drugs for treatment of non-neuropsychiatric conditions | Hoofd Techniek/Wetenschap/O&O | - |
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops medications for treatment of diseases associated with vascular dysfunction | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Paul van Slyke
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
University of Toronto
University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops medications for treatment of diseases associated with vascular dysfunction | Health Technology |
Pharmadrug, Inc.
Pharmadrug, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development of cannabis-infused edible products and oil extracts | Health Technology |
Sairiyo Therapeutics, Inc.
Sairiyo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures psychedelics drugs for treatment of non-neuropsychiatric conditions | Health Technology |
















